MOSAIC - Vaccine Exposed Group 10
The population is composed of individuals 18 years of age or older, in good health or with mild or moderate stable co-morbidities, who have had one dose of Astra Zeneca vaccine for less than 55 days since injection or are booked to receive the first dose of Astra Zeneca, and will receive the second injection (0,20 mg/mL) of Moderna vaccine via intramuscular injection in the deltoid muscle after 112 days.
The population is composed of individuals 18 years of age or older, in good health or with mild or moderate stable co-morbidities, who have had one dose of Astra Zeneca vaccine for less than 55 days since injection or are booked to receive the first dose of Astra Zeneca, and will receive the second injection (0,20 mg/mL) of Moderna vaccine via intramuscular injection in the deltoid muscle after 112 days.
-
Minimum age
-
18
-
Newborns
-
-
Twins
-
-
Countries
-
-
Territory
-
-
Ethnic Origin
-
-
Health Status
-
Inclusion: - In good health or with mild or moderate stable co-morbidities.
Exclusion: - Any confirmed or suspected immunosuppressive or immunodeficient state
- Asplenia, or immunosuppressant medication within the past 6 months except short term oral steroids (≤14 days duration) or topical steroids
- Current diagnosis or treatment for cancer (except basal cell carcinoma of the skin)
- Bleeding disorder or history of significant bleeding following IM injections or venipuncture
- History of laboratory-confirmed COVID-19 disease prior to enrolment.
-
Other Criteria
-
Inclusion: - Have received or are booked to receive the first dose of an authorized COVID-19 vaccine in the 55 days prior to Visit 1
- If female of child-bearing potential and heterosexually active, has practiced adequate contraception for 30 days prior to injection, has a negative pregnancy test on the day of injection, and has agreed to continue adequate contraception until 3 months after the second dose of study vaccine.
Exclusion: - Administration of immunoglobulins and/or any blood products within 3 months,
- Allergy to any study vaccine or any active substance,
- Continuous use of anticoagulants,
- Pregnancy or intent to become pregnant during the study or within 3 months of the last dose of study vaccine.
-
Supplementary Information about selection criteria
-
Participants will be recruited from the communities in which CTN study sites are situated; these are urban centres in Canada. Enrolment will be open to persons of all genders and ethnicities.
-
Sources of recruitment
-
-
General Population
-
-
Supplementary Information
-
Participants were recruited using social media, media outlets, print and electronic media at vaccination centers, and by contacting persons on existing databases at each site.
-
Number of Participants
-
-
Number of Participants with Biological Samples
-